p38alfa and epigenetics on drug resistance

• Project/Area Number: 16K10044
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Nippon Medical School
• Principal Investigator: Takeshi Asano 日本医科大学, 医学部, 教授 (70277490)
• Co-Investigator(Kenkyū-buntansha): 藤田 敦士 日本医科大学, 医学部, 研究生 (50366704)
• Project Period (FY): 2016-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: 薬剤耐性 / エピジェネティクス / 抗癌剤 / p38α / 白血病 / p38 / epigenetics / methylation

Outline of Final Research Achievements

We confirmed the central role of drug resistance on certaion anti-leukemia drugs. However, because strong variabilities on the reactions of p38alfa in each cell lines were obsereved, we could not conclude the univeral role of p38alfa on drug resistance.

Academic Significance and Societal Importance of the Research Achievements

抗癌剤の薬剤耐性に関して新し治験が得られた。p38は色々な生体内の反応では重要な役割を持っており、今後の癌、特に白血病の治療において新しい薬剤耐性を克服する薬剤の開発に一つのプラットフォームを提供できると考えられる。今後、臨床分野で使用可能な薬剤の探索、開発を行っていく方向へ向かえば、現在、打つ手のない、再発、難治の癌、白血病に対して新たな治療法を提供できると考えている。

Research Products

• [Journal Article] Genome-wide DNA methylation profiling of CpG islands in a morpholino anthracycline derivative-resistant leukemia cell line: p38α as a novel candidate for resistance. (2017)
  • Author(s): Asano T, Narazaki H, and Fujita A.
  • Journal Title: Pharmacology Research & Perspectives Volume: ５ Issue: 1 Pages: e00285-e00285
  • DOI: 10.1002/prp2.285
  • Peer Reviewed / Open Access / Acknowledgement Compliant